Back to top
more

HCA Healthcare (HCA)

(Delayed Data from NYSE)

$373.33 USD

373.33
1,136,838

+7.18 (1.96%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $373.22 -0.11 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (58 out of 246)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Becton Dickinson (BDX) Earnings Surpass Estimates in Q2

by Zacks Equity Research

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.

Zacks Equity Research

Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong international and domestic pump sales and shipment boosted the first-quarter top line.

Zacks Equity Research

NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.

Zacks Equity Research

Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.

Zacks Equity Research

Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Cerner's (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in gross margin.

Zacks Equity Research

Allscripts (MDRX) Inches Up 0.3% on Earnings Beat in Q1

by Zacks Equity Research

Allscripts (MDRX) witnesses a year- over- year surge in earnings during Q1.

Zacks Equity Research

Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.

Zacks Equity Research

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.

Zacks Equity Research

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) first-quarter results benefit from strong segmental performance.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Globus Medical's (GMED) first-quarter 2021 revenues improved year over year on strength in Enabling Technologies and U.S. Spine.

Zacks Equity Research

AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.

Zacks Equity Research

Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.

Zacks Equity Research

Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up

by Zacks Equity Research

Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.

Zacks Equity Research

Henry Schein (HSIC) Q1 Earnings Top Estimates, '21 EPS View Up

by Zacks Equity Research

Henry Schein (HSIC) sees robust segmental performance in Q1 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.

Zacks Equity Research

IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up

by Zacks Equity Research

IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.

Zacks Equity Research

CVS Health (CVS) Q1 Earnings Beat Estimates, EPS View Up

by Zacks Equity Research

CVS Health's (CVS) revenues across all the three operating segments improve in Q1. Increased guidance amid the pandemic scenario is another positive.

Zacks Equity Research

QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.

Zacks Equity Research

Magellan Health's (MGLN) Q1 Earnings Beat Mark, Improve Y/Y

by Zacks Equity Research

Magellan Health's (MGLN) Q1 results reflect better performances by its Heathcare and Pharmacy Management segments.

Zacks Equity Research

Pacific Biosciences (PACB) Down 10.8% Despite Narrower Q1 Loss

by Zacks Equity Research

Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.

Zacks Equity Research

Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat

by Zacks Equity Research

Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.

Zacks Equity Research

Orthofix's (OFIX) Q1 Earnings Top Estimates, 2021 View Up

by Zacks Equity Research

Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.

Zacks Equity Research

Hill-Rom (HRC) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Hill-Rom's (HRC) second-quarter revenues improved year over year on continued recovery across all three business segments as well as expanded demand for critical care products.

Zacks Equity Research

Zacks.com featured highlights include: HCA Healthcare, Landstar System, East West Bancorp and Deere

by Zacks Equity Research

Zacks.com featured highlights include: HCA Healthcare, Landstar System, East West Bancorp and Deere

Zacks Equity Research

Acadia Healthcare (ACHC) Q1 Earnings Top Estimates, Rise Y/Y

by Zacks Equity Research

Acadia Healthcare (ACHC) Q1 earnings benefit from revenue gains, led by higher revenue per patient day and an increase in patient days, partly offset by a rise in expenses.

Zacks Equity Research

Ensign Group's (ENSG) Q1 Earnings Beat, 2021 EPS View Up

by Zacks Equity Research

Ensign Group's (ENSG) first-quarter results reflect better revenues and a solid performance of its Transitional and Skilled Services.